Fig. 2From: Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendationsA 3-year prostate cancer-specific survival of insured patients with localized prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). B 3-year prostate cancer-specific survival of Medicaid patients with localized prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). C 3-year prostate cancer-specific survival of uninsured patients with localized prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). D 3-year prostate cancer-specific survival of insured patients with regional prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). E 3-year prostate cancer-specific survival of Medicaid patients with regional prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). F 3-year prostate cancer-specific survival of uninsured patients with regional prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). G 3-year prostate cancer-specific survival of insured patients with metastatic prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). H 3-year prostate cancer-specific survival of Medicaid patients with metastatic prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). I 3-year prostate cancer-specific survival of uninsured patients with metastatic prostate cancer in 2010–2012 (pre-USPSTF era) and 2014–2016 (post-USPSTF era). Prostate cancer-specific survival of insured patients across all stages of prostate cancer worsened from 2010–2012 to 2014–2016, while Medicaid and uninsured patients across all stages did not changeBack to article page